Virpax Pharmaceuticals Inc.
Berwyn
About Virpax Pharmaceuticals Inc.
Virpax is pioneering advanced healthcare solutions with Probudur, its flagship product leveraging proprietary liposomal encapsulation. Designed for sustained release, Probudur delivers local anesthetic at the wound/incision site, effectively managing post-operative pain for an extended 96 hours. Collaborating through Cooperative Research and Development Agreements (CRADA) and partnering with prestigious institutions like the National Institute of Health/NCATS and U.S.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $58.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2025)
- Ticker: nasdaq:VRPX
- Website: virpaxpharma.com
- Phone: 610.727.4597
Industries & Categories
Biopharma, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/virpax-pharmaceuticals-inc-61204 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.